

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-15 (canceled)

Claim 16 (previously presented): A method of preventing or treating restenosis comprising administering a therapeutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal, wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide is present in free form or in pharmaceutically acceptable salt form.

Claim 17 (withdrawn): A method of preventing or treating atherosclerosis comprising administering a therapeutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal, wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide is present in free form or in pharmaceutically acceptable salt form.

Claim 18 (withdrawn): A method of preventing or treating transplant-induced disorders comprising administering a therapeutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal, wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide is present in free form or in pharmaceutically acceptable salt form.

Claim 19 (withdrawn): The method of claim 18 wherein the transplant-induced disorders is obliterative bronchiolitis.

Claim 20 (withdrawn): A method of preventing the invasion of cells by bacteria comprising administering a therapeutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal, wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide is present in free form or in pharmaceutically acceptable salt form.

Claim 21 (withdrawn): The method of claim 20 wherein the bacteria is *Porphyromonas gingivalis*.

Claim 22 (previously presented): A method of preventing or treating restenosis comprising administering a therapeutically effective amount of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

Claim 23 (withdrawn): A method of preventing or treating atherosclerosis comprising administering a therapeutically effective amount of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

Claim 24 (withdrawn): A method of preventing or treating transplant-induced disorders comprising administering a therapeutically effective amount of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

Claim 25 (withdrawn): The method of claim 18 wherein the transplant-induced disorders is obliterative bronchiolitis.

Claim 26 (withdrawn): A method of preventing the invasion of cells by bacteria comprising administering a therapeutically effective amount of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

Claim 27 (withdrawn): The method of claim 20 wherein the bacteria is Porphyromonas gingivalis.

Claim 28 (previously presented): A method of preventing or treating restenosis comprising administering a therapeutically effective amount of the β -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

Claim 29 (withdrawn): A method of preventing or treating atherosclerosis comprising administering a therapeutically effective amount of the β -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phey]benzamide to a warm-blooded animal.

Claim 30 (withdrawn): A method of preventing or treating transplant-induced disorders comprising administering a therapeutically effective amount of the β -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal.

Claim 31 (withdrawn): The method of claim 18 wherein the transplant-induced disorders is obliterative bronchiolitis.

Claim 32 (withdrawn): A method of preventing the invasion of cells by bacteria comprising administering a therapeutically effective amount of the β -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal.

Claim 33 (withdrawn): The method of claim 20 wherein the bacteria is *Porphyromonas gingivalis*.

Claim 34 (previously presented): A method of preventing or treating restenosis comprising administering a therapeutically effective amount of the α -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal.

Claim 35 (withdrawn): A method of preventing or treating atherosclerosis comprising administering a therapeutically effective amount of the α -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal.

Claim 36 (withdrawn): A method of preventing or treating transplant-induced disorders comprising administering a therapeutically effective amount of the α -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal.

Claim 37 (withdrawn): The method of claim 18 wherein the transplant-induced disorders is obliterative bronchiolitis.

Claim 38 (withdrawn): A method of preventing the invasion of cells by bacteria comprising administering a therapeutically effective amount of the α -crystal form of the methanesulfonic

acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide to a warm-blooded animal.

Claim 39 (withdrawn): The method of claim 20 wherein the bacteria is *Porphyromonas gingivalis*.


Claim 40 (withdrawn): A pharmaceutical composition comprising 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide and a pharmaceutically acceptable carrier.

Claim 41 (withdrawn): A pharmaceutical composition comprising the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide and a pharmaceutically acceptable carrier.

Claim 42 (withdrawn): A pharmaceutical composition comprising the β -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide and a pharmaceutically acceptable carrier.

Claim 43 (withdrawn): A pharmaceutical composition comprising the α -crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenylbenzamide and a pharmaceutically acceptable carrier.

Claim 44 (currently amended): ~~A method of preventing or treating~~ The method of claim 28 wherein the prevention or treatment of restenosis comprising comprises administering a therapeutically effective amount of a crystalline form of the monomethanesulfonic acid addition salt of a compound of formula I,



which is non-hygroscopic in a glass climatic chamber at 25 °C and relative humidities up to and including 93%, to a patient in need thereof.